Last updated on May 2019
Survey Study for Velaglucerase Alfa (VPRIV) in Japan
Brief description of study
The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.
Clinical Study Identifier: NCT03625882